BioLineRx shares are trading higher after the company announces that the first patient has been dosed in its Phase 1/2A study of GLIX-1 for glioblastoma and other high-grade gliomas.

Benzinga Newsdesk www.benzinga.com Positive 94.4%

Neg 0% Neu 0% Pos 94.4%

Comments

No comments yet. Be the first!